MARTINSRIED, Germany, Oct. 8, 2001 (PRIMEZONE) -- Munich-based Ingenium Pharmaceuticals AG has opened a subsidiary in Boston and expanded its international business development activities by appointing David M. Konys as Vice President of Corporate Development, Ingenium Pharmaceuticals Inc.
David Konys joins Ingenium from Biogen, Inc., where he was most recently Director of Commercial Projects. During his 15-year career with Biogen, Mr. Konys held positions of increasing responsibility in project management, marketing, operations, and business development. His international responsibilities included establishing Biogen Canada, Inc. and overseeing the launch of commercial products into the Canadian market.
In his role as Vice President of Corporate Development, Mr. Konys will lead the effort to commercialize Ingenium's Deductive Genomics technology. In addition, he will provide strategic planning direction and evaluate in-licensing opportunities to broaden Ingenium's drug development capabilities.
"I am very excited to have the chance to join Ingenium at a key stage in its development," Mr. Konys said. "I am looking forward to contributing to the development of this biotherapeutics company that has such enormous potential for rapid growth based on its innovative Deductive Genomics technology."
"Opening up a US subsidiary for corporate development purposes will position Ingenium to capture the many business opportunities that exist there. We intend to fully leverage our Deductive Genomics technology by building strategic alliances on both sides of the Atlantic," said Dr. Nehls, President of Ingenium Inc. and CEO of Ingenium AG. "We are very fortunate to have David Konys join our team. The breadth of his experience in managing the growth of new and expanding operations will significantly help our efforts in realizing the full commercial value of our technology, which is ultimately the basis for increasing shareholder value."
Ingenium Pharmaceuticals AG, founded in 1998, is a privately held company based in Martinsried, Germany. Ingenium is the first functional Genomics Company that has developed and unified all of the required technologies to engage in the world's largest and most comprehensive Deductive Genomics program using a mammalian model system. Deductive Genomics, unlike conventional gene-to-function approaches, enables the researcher to screen the entire genome for novel medically important biologies. These data then lead to the target genes, and the novel biochemical pathways responsible for the observations. The advantage in reversing the flow of functional genomics lies in significantly increased research productivity and dramatic savings in drug development time and costs.
Please click on link to view formatted press release. If you have any questions or queries please do not hesitate to contact Noonan Russo on +44 20 77264452.